CRDL Stock Forecast 2025-2026
Distance to CRDL Price Targets
CRDL Price Momentum
10 Quality Stocks Worth Considering Now
Researching Cardiol Therapeutics (CRDL) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CRDL and similar high-potential opportunities.
Latest CRDL Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, CRDL has a bullish consensus with a median price target of $8.81 (ranging from $8.27 to $10.02). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $1.01, the median forecast implies a 772.6% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRDL Analyst Ratings
CRDL Price Target Range
Latest CRDL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRDL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2025 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Apr 7, 2025 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Feb 24, 2025 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Dec 18, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Jun 26, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $10.00 |
| Jun 14, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Jun 7, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| May 23, 2024 | Canaccord Genuity | Edward Nash | Buy | Maintains | $8.00 |
| May 14, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Apr 22, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Initiates | $9.00 |
| Aug 14, 2023 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $3.00 |
| May 19, 2023 | Canaccord Genuity | Edward Nash | Buy | Maintains | $6.00 |
| Dec 22, 2021 | Canaccord Genuity | Buy | Initiates | $0.00 | |
| Dec 22, 2021 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
| Dec 17, 2021 | Cantor Fitzgerald | Charles Duncan | Overweight | Initiates | $8.00 |
| Dec 3, 2021 | Canaccord Genuity | Buy | Initiates | $0.00 |
Cardiol Therapeutics Inc. (CRDL) Competitors
The following stocks are similar to Cardiol Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cardiol Therapeutics Inc. (CRDL) Financial Data
Cardiol Therapeutics Inc. has a market capitalization of $83.44M with a P/E ratio of -2.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -138.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cardiol Therapeutics Inc. (CRDL) Business Model
About Cardiol Therapeutics Inc.
Develops therapies for heart diseases.
Cardiol Therapeutics operates as a clinical-stage biotechnology company focused on creating innovative anti-inflammatory and anti-fibrotic treatments for severe cardiovascular conditions. The company generates revenue through the research and development of its therapies, particularly utilizing cannabidiol (CBD) to address key medical needs in heart disease.
Headquartered in Oakville, Ontario, Cardiol is committed to rigorous scientific research and aims to redefine therapeutic protocols for heart disease treatment, positioning itself as a significant player in the pharmaceutical and healthcare sectors.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
18
CEO
Mr. David G. Elsley MBA
Country
Canada
IPO Year
2018
Website
www.cardiolrx.comCardiol Therapeutics Inc. (CRDL) Latest News & Analysis
Northwestern University has randomized the first patient for a study on CardiolRx™ in recurrent pericarditis. Results may support a New Drug Application pending MAVERIC outcomes.
The successful trial of CardiolRx™ could lead to FDA approval, impacting Cardiol's market position and potential revenue, influencing investor sentiment and stock performance.
Cardiol Therapeutics reported positive Phase II results for CardiolRx™ in recurrent pericarditis, advancing to Phase III trials. They also completed enrollment in the ARCHER trial with data due Q2 2025. The FDA granted Orphan Drug Designation, and the company has $30.6 million cash to fund operations into Q3 2026.
Positive Phase II results for CardiolRx™ and FDA Orphan Drug Designation enhance growth prospects for Cardiol Therapeutics, while sufficient cash reserves ensure continued operations and trials.
Cardiol Therapeutics Inc. (NASDAQ: CRDL) will present at the TD Cowen Health Care Conference on March 5, 2025, at 11:10 a.m. EST. A webcast replay will be available on their website.
Cardiol Therapeutics' presentation at a major healthcare conference highlights its commitment to innovation in heart disease treatment, potentially influencing investor confidence and stock performance.
Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failure
1 month agoCardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) reports research indicating its cannabidiol-based drug candidate CRD-38 may aid heart failure treatment, showing positive effects on mitochondrial function in preclinical studies.
Positive research findings for Cardiol's CRD-38 could enhance its market potential, influence stock performance, and attract investor interest in the biotech sector focused on heart treatments.
Cardiol Therapeutics reported positive research results on its cannabidiol formulation CRD-38, showing improvements in cardiac function and reduced heart failure mechanisms, published in JACBTS.
Positive research results on Cardiol's CRD-38 could enhance its market position, attract investment, and drive stock prices, as effective heart failure treatments are in high demand.
Cardiol Therapeutics' CardiolRx™ is in trials for heart conditions and holds orphan drug status. Despite a 40% stock decline, it has $15.9M cash and a $99M market cap, with potential catalysts ahead.
Cardiol Therapeutics' promising drug pipeline and strong cash position suggest potential for growth, despite recent stock decline. Upcoming trial results and partnerships could drive significant value appreciation.
Frequently Asked Questions About CRDL Stock
What is Cardiol Therapeutics Inc.'s (CRDL) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Cardiol Therapeutics Inc. (CRDL) has a median price target of $8.81. The highest price target is $10.02 and the lowest is $8.27.
Is CRDL stock a good investment in 2025?
According to current analyst ratings, CRDL has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRDL stock?
Wall Street analysts predict CRDL stock could reach $8.81 in the next 12 months. This represents a 772.6% increase from the current price of $1.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cardiol Therapeutics Inc.'s business model?
Cardiol Therapeutics operates as a clinical-stage biotechnology company focused on creating innovative anti-inflammatory and anti-fibrotic treatments for severe cardiovascular conditions. The company generates revenue through the research and development of its therapies, particularly utilizing cannabidiol (CBD) to address key medical needs in heart disease.
What is the highest forecasted price for CRDL Cardiol Therapeutics Inc.?
The highest price target for CRDL is $10.02 from at , which represents a 892.4% increase from the current price of $1.01.
What is the lowest forecasted price for CRDL Cardiol Therapeutics Inc.?
The lowest price target for CRDL is $8.27 from at , which represents a 718.5% increase from the current price of $1.01.
What is the overall CRDL consensus from analysts for Cardiol Therapeutics Inc.?
The overall analyst consensus for CRDL is bullish. Out of 5 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.81.
How accurate are CRDL stock price projections?
Stock price projections, including those for Cardiol Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.